Supreme Court to hear Medtronic case
The US Supreme Court has agreed to hear a patent infringement case between medical device manufacturers Medtronic and Boston Scientific.
RuiYi joins with Genor to develop cancer treatment
San Diego-Shanghai biotechnology startup RuiYi Inc has entered into an exclusive license and collaborative development agreement with Shanghai-based Genor BioPharma to develop the RYI-008 molecule in China.
Ideas Matter: the importance of IP in the fight against cancer
On May 14, healthcare experts met in London to share and discuss developments in cancer detection, prevention, treatment and maintenance, and how IP protection and management are vital in attracting investment.
Ideas Matter: Philips and Microsoft in life sciences
At the Ideas Matter roundtable last week LSIPR spoke to Maaike van Velzen, general manager of Philips Group Innovation’s IP and Standards division, about the importance of using IP to promote the company’s vision.
IP key to US biosimilars success – report
Strong IP knowledge is one of four key factors to succeeding in the burgeoning US biosimilars market, according to an industry report.
Monsanto v Bowman: Supreme Court rejects “blame-the-bean” defence
The US Supreme Court has decided unanimously in favour of agricultural company Monsanto in its patent battle against Indiana farmer Vernon Bowman.
AstraZeneca loses Seroquel appeal
The UK Court of Appeal has upheld the High Court’s decision that AstraZeneca’s patent for a sustained release formulation of anti-psychotic drug quetiapine is invalid.
Pfizer sells Viagra online to curb counterfeit trade
Pfizer has announced it will sell its erectile dysfunction pill Viagra online in an effort to counter the rising threat of bogus online pharmacies.
Acura sues Ranbaxy over abuse-resistant generic
Acura Pharmaceuticals has sued Ranbaxy Laboratories to keep it from releasing a generic version of its immediate release tablet formulation of painkiller Oxecta.
Cyclacel sells cancer drug patents to Celgene
Cyclacel Pharmaceuticals has entered into a definitive agreement to sell four of its patents related to the use of the romidepsin injection to Celgene Corporation.
